Prudential Financial
CMPX icon

Prudential Financial’s Compass Therapeutics CMPX Stock Holding History

Prudential Financial’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.6K Sell
21,720
-472,580
-96% -$1.4M ﹤0.01% 2423
2026
Q1 		$2.61M Buy
494,300
+179,550
+57% +$1.04M ﹤0.01% 1206
2025
Q4 		$1.69M Buy
+314,750
New +$1.45M ﹤0.01% 1393

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Prudential Financial's CMPX Position: Q2 2026 in Review

Prudential Financial reduced its Compass Therapeutics (CMPX) stake by 96% in Q2 2026, selling an estimated $1.4M and leaving 21,720 shares worth $47.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2423.

Prudential Financial first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.61M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Prudential Financial held 21,720 shares of Compass Therapeutics worth $47.6K as of Q2 2026.
  • Prudential Financial sold 472,580 Compass Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Compass Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2423 holding.
  • Prudential Financial first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Prudential Financial's Compass Therapeutics position peaked at $2.61M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.